trazodone has been researched along with Benign Neoplasms in 6 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "After multivariate analysis, dehydration (0." | 1.56 | Reversibility of delirium in Ill-hospitalized cancer patients: Does underlying etiology matter? ( Amano, K; Iwase, S; Kaneishi, K; Maeda, I; Matsuda, Y; Morita, T; Ogawa, A; Sakashita, A; Watanabe, H; Yamauchi, T; Yoshiuchi, K, 2020) |
| "Patients with cancer often experience insomnia." | 1.39 | An observational study of insomnia and nightmare treated with trazodone in patients with advanced cancer. ( Kabeshita, Y; Matsuda, Y; Murai, T; Ohno, Y; Okamoto, Y; Okazaki, N; Tanimukai, H; Tsuneto, S, 2013) |
| "Trazodone is a unique antidepressant, which blocks the postsynaptic serotonin (5-HT) receptors, 5-HT(2A) and 5-HT(2C), and weakly inhibits presynaptic 5-HT transporters." | 1.34 | Does trazodone have a role in palliating symptoms? ( Davis, MP, 2007) |
| " The assay was applied to a pharmacokinetic study in mice to determine dosing schedules that would approximate therapeutic ZD6474 levels determined in humans." | 1.33 | Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues. ( Bradshaw, EL; Gustafson, DL; Long, ME; Zirrolli, JA, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuda, Y | 2 |
| Maeda, I | 2 |
| Morita, T | 1 |
| Yamauchi, T | 1 |
| Sakashita, A | 1 |
| Watanabe, H | 1 |
| Kaneishi, K | 1 |
| Amano, K | 2 |
| Iwase, S | 2 |
| Ogawa, A | 2 |
| Yoshiuchi, K | 2 |
| Inoue, S | 1 |
| Uemura, K | 1 |
| Tanimukai, H | 2 |
| Hatano, Y | 1 |
| Yokomichi, N | 1 |
| Tagami, K | 1 |
| Murai, T | 1 |
| Okazaki, N | 1 |
| Okamoto, Y | 1 |
| Kabeshita, Y | 1 |
| Ohno, Y | 1 |
| Tsuneto, S | 1 |
| Zirrolli, JA | 1 |
| Bradshaw, EL | 1 |
| Long, ME | 1 |
| Gustafson, DL | 1 |
| Davis, MP | 1 |
| Ventafridda, V | 1 |
| Bonezzi, C | 1 |
| Caraceni, A | 1 |
| De Conno, F | 1 |
| Guarise, G | 1 |
| Ramella, G | 1 |
| Saita, L | 1 |
| Silvani, V | 1 |
| Tamburini, M | 1 |
| Toscani, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Trazodone vs. Quetiapine for the Treatment of ICU Delirium: A Prospective Observational Pilot Study[NCT05307003] | 60 participants (Anticipated) | Observational | 2023-04-01 | Recruiting | |||
| Comparison of Trazodone vs Quetiapine vs Placebo for the Treatment of ICU Delirium: A Randomized Controlled Trial (The TraQ Study)[NCT05085808] | Phase 4 | 30 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for trazodone and Benign Neoplasms
| Article | Year |
|---|---|
Antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone.
Topics: Adult; Aged; Amitriptyline; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Humans; | 1987 |
5 other studies available for trazodone and Benign Neoplasms
| Article | Year |
|---|---|
Reversibility of delirium in Ill-hospitalized cancer patients: Does underlying etiology matter?
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cancer Care Facilities; Comorbidity; Dehydration; Del | 2020 |
Low-Dose Trazodone for Delirium in Patients with Cancer Who Received Specialist Palliative Care: A Multicenter Prospective Study.
Topics: Aged; Delirium; Humans; Japan; Neoplasms; Palliative Care; Prospective Studies; Trazodone | 2021 |
Low-Dose Trazodone for Delirium in Patients with Cancer Who Received Specialist Palliative Care: A Multicenter Prospective Study.
Topics: Aged; Delirium; Humans; Japan; Neoplasms; Palliative Care; Prospective Studies; Trazodone | 2021 |
Low-Dose Trazodone for Delirium in Patients with Cancer Who Received Specialist Palliative Care: A Multicenter Prospective Study.
Topics: Aged; Delirium; Humans; Japan; Neoplasms; Palliative Care; Prospective Studies; Trazodone | 2021 |
Low-Dose Trazodone for Delirium in Patients with Cancer Who Received Specialist Palliative Care: A Multicenter Prospective Study.
Topics: Aged; Delirium; Humans; Japan; Neoplasms; Palliative Care; Prospective Studies; Trazodone | 2021 |
An observational study of insomnia and nightmare treated with trazodone in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Dreams; Female; Humans; Hy | 2013 |
Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues.
Topics: Acetates; Animals; Antineoplastic Agents; Calibration; Chemistry, Pharmaceutical; Chromatography; Ch | 2005 |
Does trazodone have a role in palliating symptoms?
Topics: Antidepressive Agents, Second-Generation; Depression; Drug Interactions; Fluoxetine; Humans; Neoplas | 2007 |